Disclaimer
is pocket guide attempts to define principles of practice that should produce high-quality patient
care. It is applicable to specialists, primary care, and providers at all levels. is pocket guide should
not be considered exclusive of other methods of care reasonably directed at obtaining the same
results. e ultimate judgment concerning the propriety of any course of conduct must be made by
the clinician aer consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated
with the distributor of this clinical reference tool.
Abbreviations
cTTP, hereditary or congenital TTP; FVIII, factor VIII; INR, international normalized
ratio; iTTP, immune-mediated TTP; MCV, mean corposcular value; SCT, stem cell
transplantation; TMA, thrombotic microangiopathy; TPE, therapeutic plasma exchange;
TTP, thrombotic thrombocytopenic purpura
e guidelines provide evidence-based recommendations that have been developed using
GR ADE (Grading of Recommendations Assessment, Development, and Evaluation)
methodolog y. GR ADE involves structured literature review, systematic reviews and meta-
analyses of combined data, and expert discussion to assess the certainty in the evidence and
determine the strength of each recommendation.
Source
X. Long Zheng, Sara K. Vesely, Spero R. Cataland, et al. ISTH Guidelines for the Diagnosis
of rombotic rombocytopenic Purpura. Journal of rombosis and Haemostasis. 2020 July
doi:10.1111/jth.15006.
X. Long Zheng, Sara K. Vesely, Spero R. Cataland, et al. ISTH Guidelines for Treatment of
rombotic rombocytopenic Purpura. Journal of rombosis and Haemostasis. 2020 July
doi:10.1111/jth.15010.
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2020 All rights reserved
ISTHTTP09203
MAT-GLB-2100232-v1.0-02/2021
This educational resource is provided by Sanofi Genzyme
